measles vaccine

measles vaccine is a live attenuated immunization that provides robust protection against measles, a highly contagious viral disease. Its development, led by pioneers like John F. Enders and Maurice Hilleman, represents a landmark achievement in virology and public health. Widespread administration, often combined with vaccines for mumps and rubella in the MMR vaccine, has dramatically reduced global morbidity and mortality.

History

The quest for a measles vaccine intensified following the isolation of the virus in 1954 by John F. Enders and Thomas C. Peebles at Boston Children's Hospital. Enders' team subsequently developed an attenuated strain, leading to the first licensed vaccine in the United States in 1963, known as the Edmonston-Enders strain. Concurrently, Maurice Hilleman at the Merck Institute for Therapeutic Research developed his own attenuated version, which was further weakened to create the Moraten strain that became standard in the Americas. The World Health Organization launched the Expanded Programme on Immunization in 1974, incorporating the vaccine into routine childhood programs globally. Landmark studies, including research by Samuel L. Katz, confirmed its efficacy and safety profile, paving the way for mass vaccination campaigns.

Medical uses

The vaccine is indicated for the primary immunization of children, typically administered as a two-dose series, with the first dose given at 12–15 months of age and the second before school entry. It is a core component of the MMR and MMRV combination vaccines recommended by the Advisory Committee on Immunization Practices and the American Academy of Pediatrics. In outbreak settings, post-exposure prophylaxis may be recommended for susceptible individuals. The World Health Organization includes it on its Model List of Essential Medicines, and it is crucial for achieving herd immunity, which protects populations in communities with high vaccination coverage. International travel to endemic regions often requires proof of vaccination.

Adverse effects

Most adverse reactions are mild and transient, including fever, malaise, and a transient rash occurring 5–12 days post-vaccination. Pain or redness at the injection site is common. A rare association exists between the MMR vaccine and febrile seizures, typically occurring 6–14 days after the first dose. Extensive investigation by organizations like the Institute of Medicine and the Cochrane Collaboration has found no causal link to autism, a claim originating from a now-retracted 1998 paper by Andrew Wakefield in The Lancet. Severe allergic reactions, such as anaphylaxis, are extremely rare. Contraindications include pregnancy, severe immunodeficiency (e.g., from advanced HIV or chemotherapy), and a history of severe allergic reaction to components like gelatin or neomycin.

Society and culture

Vaccination policies have been shaped by major public health institutions like the Centers for Disease Control and Prevention and the World Health Organization, which spearheaded the Measles & Rubella Initiative aiming for global elimination. The now-debunked link to autism, promoted by Andrew Wakefield, significantly impacted vaccine hesitancy in regions like the United Kingdom and parts of the United States, leading to outbreaks in communities such as Disneyland in 2015. Legal frameworks, including rulings from the U.S. Court of Federal Claims under the National Vaccine Injury Compensation Program, address rare injury claims. Cultural and religious objections from groups like some within the Amish communities have also presented challenges to achieving uniform vaccination coverage.

Research

Ongoing research focuses on developing alternative vaccine platforms, such as DNA vaccines and virus-like particles, to improve thermostability for use in resource-limited settings without reliable cold chain infrastructure. Studies investigate the duration of immunity and the potential need for booster doses in adulthood. The World Health Organization and partners like Gavi, the Vaccine Alliance support research into microneedle patch delivery systems to simplify administration. Serosurveillance studies, including those conducted by the European Centre for Disease Prevention and Control, monitor waning immunity and vaccine effectiveness against emerging viral genotypes. Research also continues into the vaccine's potential non-specific effects on overall childhood mortality.

Category:Vaccines Category:World Health Organization essential medicines